By Product & Service: Reagents, Kits, and Consumables Dominate the Market

The market is segmented into reagents, kits, and consumables; instruments; and software & services. In 2024, reagents, kits, and consumables accounted for the largest market share and are expected to maintain dominance through 2030.

Why This Segment Leads:

• High testing frequency and recurring demand among end users
• Critical role in ensuring test reliability and sensitivity
• Continuous product innovation in multiplex assays and rapid test kits
• Increasing use of AI-enhanced molecular reagents for faster data interpretation

This recurring revenue stream is vital for diagnostic companies, as consumable purchases represent a stable, long-term growth opportunity.

By Sample Type: Blood, Serum, and Plasma Lead Testing Applications

Based on sample type, the market is segmented into blood, serum, and plasma; urine; and other samples. In 2024, blood, serum, and plasma samples dominated due to their rich diagnostic value and ability to reveal multiple biomarkers and pathogens.

These samples provide comprehensive biological data for PCR, ELISA, NGS, and immunodiagnostic assays, enabling healthcare professionals to:

• Detect infections in early stages
• Monitor disease progression
• Support personalized therapy planning

The continued evolution of liquid biopsy and microfluidic diagnostic platforms is expected to further enhance blood-based testing capabilities.

By Technology: Molecular Diagnostics Driving Accuracy and Speed

The infectious disease diagnostics market is transforming through the adoption of advanced molecular technologies, including:

• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Isothermal Amplification
• Immunodiagnostics (ELISA, rapid antigen tests)

Emerging Trends:

• Miniaturized point-of-care PCR platforms
• Integration of AI-based image and data analysis
• Multi-pathogen syndromic testing panels
• Cloud-enabled diagnostic connectivity for remote healthcare settings

The fusion of molecular diagnostics with digital health technologies enables faster, decentralized testing, improving outbreak management and patient outcomes.

By Region: North America Leads Global Market Share

North America accounted for the largest share of the infectious disease diagnostics market in 2024, supported by:

• Advanced healthcare infrastructure
• High diagnostic testing rates
• Early adoption of AI and automation in laboratories
• Continuous R&D investment by leading diagnostic manufacturers

The United States remains a global innovation hub, driven by FDA approvals, strong public-private partnerships, and government initiatives to strengthen disease surveillance systems.

Meanwhile, the Asia Pacific region is expected to witness the fastest growth, supported by:

• Rapid healthcare modernization in China, India, and South Korea
• Expanding diagnostic access in rural and underserved areas
• Growing focus on infectious disease prevention and control programs

Innovation Spotlight: AI and Point-of-Care Diagnostics Revolutionizing Testing

Emerging technologies are transforming how healthcare providers detect and manage infectious diseases:

• AI-powered diagnostic platforms enhance test interpretation, reducing false negatives and improving clinical decision-making.
• Portable point-of-care devices enable testing in decentralized environments, from clinics to home care.
• Cloud-based connectivity supports real-time data sharing and outbreak monitoring.
• NGS-based pathogen identification facilitates comprehensive surveillance of evolving strains and resistance patterns.

These innovations are central to achieving global health resilience and precision-based public health strategies.

Key Market Players

Leading companies shaping the infectious disease diagnostics landscape include: F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Danaher Corporation (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), and Bio-Rad Laboratories, Inc. (US).

These companies are investing in AI-enabled diagnostic automation, portable molecular testing, and syndromic panels, driving innovation across clinical and research applications.

Conclusion: Diagnostics at the Core of Global Health Preparedness

As infectious threats evolve, accurate, rapid, and decentralized testing has become essential to global health strategies. The infectious disease diagnostics market is poised for sustained growth, powered by molecular innovations, AI-driven platforms, and expanding diagnostic infrastructure in both developed and emerging economies.

With increasing global health challenges, diagnostics remains the cornerstone of effective disease prevention, timely treatment, and population-level surveillance.